China’s National Healthcare Security Administration (NHSA) announced on Jan. 10 that it will not include Pfizer’s Paxlovid in its national reimbursement plan due to its high cost.
The negotiation between China and Pfizer on Tuesday failed because Pfizer considered China “a middle-income country,” and the price proposed by Beijing was lower than what Pfizer would have accepted, according to several media outlets.
